CRISPRi-based screen of autism spectrum disorder risk genes in microglia uncovers roles of ADNP in microglia endocytosis and synaptic pruning
- PMID: 40188316
- PMCID: PMC12339388
- DOI: 10.1038/s41380-025-02997-z
CRISPRi-based screen of autism spectrum disorder risk genes in microglia uncovers roles of ADNP in microglia endocytosis and synaptic pruning
Abstract
Autism Spectrum Disorders (ASD) are a set of neurodevelopmental disorders with complex biology. The identification of ASD risk genes from exome-wide association studies and de novo variation analyses has enabled mechanistic investigations into how ASD-risk genes alter development. Most functional genomics studies have focused on the role of these genes in neurons and neural progenitor cells. However, roles for ASD risk genes in other cell types are largely uncharacterized. There is evidence from postmortem tissue that microglia, the resident immune cells of the brain, appear activated in ASD. Here, we used CRISPRi-based functional genomics to systematically assess the impact of ASD risk gene knockdown on microglia activation and phagocytosis. We developed an iPSC-derived microglia-neuron coculture system and high-throughput flow cytometry readout for synaptic pruning to enable parallel CRISPRi-based screening of phagocytosis of beads, synaptosomes, and synaptic pruning. Our screen identified ADNP, a high-confidence ASD risk genes, as a modifier of microglial synaptic pruning. We found that microglia with ADNP loss have altered endocytic trafficking, remodeled proteomes, and increased motility in coculture.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: MK is a co-scientific founder of Montara Therapeutics and serves on the Scientific Advisory Boards of Montara Therapeutics, Engine Biosciences, Casma Therapeutics, Alector, and Neurocrine, and is an advisor to Modulo Bio and Recursion Therapeutics. MK is an inventor on US Patent 11,254,933 related to CRISPRi and CRISPRa screening, and on a US Patent application on in vivo screening methods. Ethics approval and consent to participate: All methods were performed in accordance with the relevant guidelines and regulations. Experiments with previous a previously derived WTC11 iPSC line were approved by the UCSF GESCR (Study number 19-28308). Informed consent was obtained from the human subject when the WTC11 was originally generated.
Figures







Update of
-
CRISPRi-based screen of Autism Spectrum Disorder risk genes in microglia uncovers roles of ADNP in microglia endocytosis and synaptic pruning.bioRxiv [Preprint]. 2024 Nov 17:2024.06.01.596962. doi: 10.1101/2024.06.01.596962. bioRxiv. 2024. Update in: Mol Psychiatry. 2025 Sep;30(9):4176-4193. doi: 10.1038/s41380-025-02997-z. PMID: 39605704 Free PMC article. Updated. Preprint.
References
-
- Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 2010;1309:83–94. - PubMed
-
- Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psychiatry. 2010;68:368–76. - PubMed
-
- Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ, Allman JM. Microglia in the cerebral cortex in autism. J. Autism Dev. Disord. 2012;42:2569–84. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical